Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
Prospective non randomized, non-comparative, dose escalation, two arms open phase I trial to
assess the safety and tolerability of capecitabine given in combination with aflibercept in
patients with measurable or evaluable, chemorefractory digestive tumors or breast tumors in
terms of the Maximum Tolerated Dose (MTD) and the Dose-Limiting Toxicities (DLTs), To
establish the Recommended Phase II Dose (RP2D) of capecitabine in combination with
Aflibercept.